Alteration in Acute Kidney Injury Potential with the Combination of Vancomycin and Imipenem-Cilastatin/Relebactam or Piperacillin/Tazobactam in a Preclinical Model
Miao He, Ernane Souza, Aleksas Matvekas, Ryan L. Crass, Manjunath P. Pai
Abstract
< 0.05) lower SCr and BUN values than VAN alone when dosed once daily. This nephroprotective effect was retained with VAN+IMP-C/REL but not VAN+TZP when IMP-C/REL and TZP were administered every 6 h. Biomarker results were concordant with histopathological findings. The VAN dose-AKI relationship can be attenuated with single daily HEDs of TZP or IMP-C/REL in mice. IMP-C/REL, but not TZP, retained a nephroprotective effect compared with VAN monotherapy when administered as fractionated doses.
Topics & Concepts
CilastatinPiperacillin/tazobactamMedicineAcute kidney injuryCreatinineDosingBlood urea nitrogenPiperacillinImipenem/cilastatinPharmacologyTazobactamVancomycinImipenemAntibacterial agentInternal medicineCombination therapyRenal functionUrologyAntibioticsBiologyMicrobiologyStaphylococcus aureusBacteriaAntibiotic resistanceGeneticsPseudomonas aeruginosaAntimicrobial Resistance in StaphylococcusAcute Kidney Injury ResearchAntibiotics Pharmacokinetics and Efficacy